BioSpace News Archive

Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson , Heska’s President & Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday January 13, 2021 at

DURECT Corporation announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.

Neuronaute® EEG System and IceCap® bring Comprehensive Remote Electroencephalography Monitoring Services to People Living with Neurological Disorders.

Researchers have produced an innovative breakthrough to tend to Atopic Dermatitis. This is the first time that a herbo - mineral drug has been discovered.

PharmaEssentia to Present at the 39 th Virtual Annual J.P. Morgan Healthcare Conference

Scott Giacobello Appointed to Board of Directors Scott Forrest, Ph.D., Promoted to Chief Financial Officer

Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST. The pane

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Chief Executive Officer Dr. Frank Bedu-Addo will be presenting at H.C. Wainwright’s BioConnect virtual conference. PDS Biotech’s presentation will be available on-demand beginning January 11, 2021

Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all c

- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo (p<0.001)[1] - KEEPsAKE-1 and KEEPsAKE-2 evaluated risankizumab in adult patients with active psoriatic arthritis, and included patients who had responded inadequately or were intolerant to biologic therapy and/or non-biologic disease-modifying anti-rheumatic drugs (DMARDs)[1]